메뉴 건너뛰기




Volumn 26, Issue 5, 2008, Pages 515-521

Monitoring biologics for the treatment of psoriasis

Author keywords

[No Author keywords available]

Indexed keywords

ALEFACEPT; EFALIZUMAB; ETANERCEPT; INFLIXIMAB; PLACEBO;

EID: 49849097373     PISSN: 0738081X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clindermatol.2007.11.001     Document Type: Article
Times cited : (8)

References (49)
  • 1
    • 0020634337 scopus 로고
    • An audit of requests for therapeutic drug monitoring of digoxin: problems and pitfalls
    • Clague H.W., Twum-Barima Y., and Carruthers S.G. An audit of requests for therapeutic drug monitoring of digoxin: problems and pitfalls. Ther Drug Monit 5 (1983) 249-254
    • (1983) Ther Drug Monit , vol.5 , pp. 249-254
    • Clague, H.W.1    Twum-Barima, Y.2    Carruthers, S.G.3
  • 2
    • 0018817836 scopus 로고
    • Basic issues in population screening for cancer
    • Cole P., and Morrison A.S. Basic issues in population screening for cancer. J Natl Cancer Inst 64 (1980) 1263-1272
    • (1980) J Natl Cancer Inst , vol.64 , pp. 1263-1272
    • Cole, P.1    Morrison, A.S.2
  • 3
    • 0032932453 scopus 로고    scopus 로고
    • Is 'routine' laboratory testing a thing of the past? Current recommendations regarding screening
    • quiz 227
    • Tabas G.H., and Vanek M.S. Is 'routine' laboratory testing a thing of the past? Current recommendations regarding screening. Postgrad Med 105 (1999) 213-220 quiz 227
    • (1999) Postgrad Med , vol.105 , pp. 213-220
    • Tabas, G.H.1    Vanek, M.S.2
  • 4
    • 21344460229 scopus 로고    scopus 로고
    • How to interpret and pursue an abnormal complete blood cell count in adults
    • Tefferi A., Hanson C.A., and Inwards D.J. How to interpret and pursue an abnormal complete blood cell count in adults. Mayo Clin Proc 80 (2005) 923-936
    • (2005) Mayo Clin Proc , vol.80 , pp. 923-936
    • Tefferi, A.1    Hanson, C.A.2    Inwards, D.J.3
  • 5
    • 0036138009 scopus 로고    scopus 로고
    • Yield and cost of individual common diagnostic tests in new primary care outpatients in Japan
    • Takemura Y., Ishida H., Inoue Y., and Beck J.R. Yield and cost of individual common diagnostic tests in new primary care outpatients in Japan. Clin Chem 48 (2002) 42-54
    • (2002) Clin Chem , vol.48 , pp. 42-54
    • Takemura, Y.1    Ishida, H.2    Inoue, Y.3    Beck, J.R.4
  • 6
    • 0038680231 scopus 로고    scopus 로고
    • Utilization of common inflammatory markers in new, symptomatic, primary care outpatients based on their cost-effectiveness
    • Takemura Y., Ishida H., and Inoue Y. Utilization of common inflammatory markers in new, symptomatic, primary care outpatients based on their cost-effectiveness. Clin Chem Lab Med 41 (2003) 668-674
    • (2003) Clin Chem Lab Med , vol.41 , pp. 668-674
    • Takemura, Y.1    Ishida, H.2    Inoue, Y.3
  • 7
    • 0030317476 scopus 로고    scopus 로고
    • Clinical approach to the patient with abnormal liver test results
    • quiz 1094-5
    • Kamath P.S. Clinical approach to the patient with abnormal liver test results. Mayo Clin Proc 71 (1996) 1089-1094 quiz 1094-5
    • (1996) Mayo Clin Proc , vol.71 , pp. 1089-1094
    • Kamath, P.S.1
  • 8
    • 0035954670 scopus 로고    scopus 로고
    • Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes
    • Ellis C.N., and Krueger G.G. Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes. N Engl J Med 345 (2001) 248-255
    • (2001) N Engl J Med , vol.345 , pp. 248-255
    • Ellis, C.N.1    Krueger, G.G.2
  • 9
    • 0036895587 scopus 로고    scopus 로고
    • A randomized, double-blind, placebo-controlled phase III study evaluating efficacy and tolerability of 2 courses of alefacept in patients with chronic plaque psoriasis
    • Krueger G.G., Papp K.A., Stough D.B., Loven K.H., Gulliver W.P., and Ellis C.N. A randomized, double-blind, placebo-controlled phase III study evaluating efficacy and tolerability of 2 courses of alefacept in patients with chronic plaque psoriasis. J Am Acad Dermatol 47 (2002) 821-833
    • (2002) J Am Acad Dermatol , vol.47 , pp. 821-833
    • Krueger, G.G.1    Papp, K.A.2    Stough, D.B.3    Loven, K.H.4    Gulliver, W.P.5    Ellis, C.N.6
  • 10
    • 0043135118 scopus 로고    scopus 로고
    • Development and use of alefacept to treat psoriasis
    • Krueger G.G., and Callis K.P. Development and use of alefacept to treat psoriasis. J Am Acad Dermatol 49 2 Suppl (2003) S87-S97
    • (2003) J Am Acad Dermatol , vol.49 , Issue.2 SUPPL
    • Krueger, G.G.1    Callis, K.P.2
  • 11
    • 33646589648 scopus 로고    scopus 로고
    • The long-term efficacy and safety of new biological therapies for psoriasis
    • Papp K.A. The long-term efficacy and safety of new biological therapies for psoriasis. Arch Dermatol Res (2006)
    • (2006) Arch Dermatol Res
    • Papp, K.A.1
  • 12
    • 0038385972 scopus 로고    scopus 로고
    • An international, randomized, double-blind, placebo-controlled phase 3 trial of intramuscular alefacept in patients with chronic plaque psoriasis
    • Lebwohl M., Christophers E., Langley R., Ortonne J.P., Roberts J., and Griffiths C.E. An international, randomized, double-blind, placebo-controlled phase 3 trial of intramuscular alefacept in patients with chronic plaque psoriasis. Arch Dermatol 139 (2003) 719-727
    • (2003) Arch Dermatol , vol.139 , pp. 719-727
    • Lebwohl, M.1    Christophers, E.2    Langley, R.3    Ortonne, J.P.4    Roberts, J.5    Griffiths, C.E.6
  • 13
    • 0348134794 scopus 로고    scopus 로고
    • Treatment of psoriasis with alefacept: correlation of clinical improvement with reductions of memory T-cell counts
    • Gordon K.B., Vaishnaw A.K., O'Gorman J., Haney J., and Menter A. Treatment of psoriasis with alefacept: correlation of clinical improvement with reductions of memory T-cell counts. Arch Dermatol 139 (2003) 1563-1570
    • (2003) Arch Dermatol , vol.139 , pp. 1563-1570
    • Gordon, K.B.1    Vaishnaw, A.K.2    O'Gorman, J.3    Haney, J.4    Menter, A.5
  • 14
    • 29244464655 scopus 로고    scopus 로고
    • The efficacy of multiple courses of alefacept in patients with moderate to severe chronic plaque psoriasis
    • Menter A., Cather J.C., Baker D., Farber H.F., Lebwohl M., and Darif M. The efficacy of multiple courses of alefacept in patients with moderate to severe chronic plaque psoriasis. J Am Acad Dermatol 54 (2006) 61-63
    • (2006) J Am Acad Dermatol , vol.54 , pp. 61-63
    • Menter, A.1    Cather, J.C.2    Baker, D.3    Farber, H.F.4    Lebwohl, M.5    Darif, M.6
  • 15
    • 49849096102 scopus 로고    scopus 로고
    • alefacept product monograph. 2003.
    • alefacept product monograph. 2003.
  • 16
    • 11844281451 scopus 로고    scopus 로고
    • Efalizumab: advancing psoriasis management with a novel, targeted T-cell modulator
    • Papp K.A. Efalizumab: advancing psoriasis management with a novel, targeted T-cell modulator. Drugs Today (Barc) 40 (2004) 889-899
    • (2004) Drugs Today (Barc) , vol.40 , pp. 889-899
    • Papp, K.A.1
  • 17
    • 0346515709 scopus 로고    scopus 로고
    • Efalizumab for patients with moderate to severe plaque psoriasis: a randomized controlled trial
    • Gordon K.B., Papp K.A., Hamilton T.K., et al. Efalizumab for patients with moderate to severe plaque psoriasis: a randomized controlled trial. Jama 290 (2003) 3073-3080
    • (2003) Jama , vol.290 , pp. 3073-3080
    • Gordon, K.B.1    Papp, K.A.2    Hamilton, T.K.3
  • 18
    • 1842591940 scopus 로고    scopus 로고
    • Impact of efalizumab on psoriasis-specific patient-reported outcomes. Results from three randomized, placebo-controlled clinical trials of moderate to severe plaque psoriasis
    • Menter A., Kosinski M., Bresnahan B.W., Papp K.A., and Ware Jr. J.E. Impact of efalizumab on psoriasis-specific patient-reported outcomes. Results from three randomized, placebo-controlled clinical trials of moderate to severe plaque psoriasis. J Drugs Dermatol 3 (2004) 27-38
    • (2004) J Drugs Dermatol , vol.3 , pp. 27-38
    • Menter, A.1    Kosinski, M.2    Bresnahan, B.W.3    Papp, K.A.4    Ware Jr., J.E.5
  • 19
    • 33646167222 scopus 로고    scopus 로고
    • Safety of efalizumab in adults with chronic moderate to severe plaque psoriasis: a phase IIIb, randomized, controlled trial
    • Papp K.A., Bressinck R., Fretzin S., et al. Safety of efalizumab in adults with chronic moderate to severe plaque psoriasis: a phase IIIb, randomized, controlled trial. Int J Dermatol 45 (2006) 605-614
    • (2006) Int J Dermatol , vol.45 , pp. 605-614
    • Papp, K.A.1    Bressinck, R.2    Fretzin, S.3
  • 20
    • 33745038011 scopus 로고    scopus 로고
    • Clinical experience acquired with the efalizumab (Raptiva) (CLEAR) trial in patients with moderate-to-severe plaque psoriasis: results from a phase III international randomized, placebo-controlled trial
    • Dubertret L., Sterry W., Bos J.D., et al. Clinical experience acquired with the efalizumab (Raptiva) (CLEAR) trial in patients with moderate-to-severe plaque psoriasis: results from a phase III international randomized, placebo-controlled trial. Br J Dermatol 155 (2006) 170-181
    • (2006) Br J Dermatol , vol.155 , pp. 170-181
    • Dubertret, L.1    Sterry, W.2    Bos, J.D.3
  • 21
    • 0345107256 scopus 로고    scopus 로고
    • A novel targeted T-cell modulator, efalizumab, for plaque psoriasis
    • Lebwohl M., Tyring S.K., Hamilton T.K., et al. A novel targeted T-cell modulator, efalizumab, for plaque psoriasis. N Engl J Med 349 (2003) 2004-2013
    • (2003) N Engl J Med , vol.349 , pp. 2004-2013
    • Lebwohl, M.1    Tyring, S.K.2    Hamilton, T.K.3
  • 22
    • 12444336904 scopus 로고    scopus 로고
    • Efficacy and safety observed during 24 weeks of efalizumab therapy in patients with moderate to severe plaque psoriasis
    • Menter A., Gordon K., Carey W., et al. Efficacy and safety observed during 24 weeks of efalizumab therapy in patients with moderate to severe plaque psoriasis. Arch Dermatol 141 (2005) 31-38
    • (2005) Arch Dermatol , vol.141 , pp. 31-38
    • Menter, A.1    Gordon, K.2    Carey, W.3
  • 23
    • 32544449299 scopus 로고    scopus 로고
    • Long-term continuous efalizumab therapy in patients with moderate to severe chronic plaque psoriasis: updated results from an ongoing trial
    • Gottlieb A.B., Hamilton T., Caro I., Kwon P., Compton P.G., and Leonardi C.L. Long-term continuous efalizumab therapy in patients with moderate to severe chronic plaque psoriasis: updated results from an ongoing trial. J Am Acad Dermatol 54 4 Suppl 1 (2006) S154-S163
    • (2006) J Am Acad Dermatol , vol.54 , Issue.4 SUPPL. 1
    • Gottlieb, A.B.1    Hamilton, T.2    Caro, I.3    Kwon, P.4    Compton, P.G.5    Leonardi, C.L.6
  • 24
    • 32544433436 scopus 로고    scopus 로고
    • Long-term management of plaque psoriasis with continuous efalizumab therapy
    • Menter A., Leonardi C.L., Sterry W., Bos J.D., and Papp K.A. Long-term management of plaque psoriasis with continuous efalizumab therapy. J Am Acad Dermatol 54 4 Suppl 1 (2006) S182-S188
    • (2006) J Am Acad Dermatol , vol.54 , Issue.4 SUPPL. 1
    • Menter, A.1    Leonardi, C.L.2    Sterry, W.3    Bos, J.D.4    Papp, K.A.5
  • 25
    • 33749330192 scopus 로고    scopus 로고
    • Safety of efalizumab in patients with moderate to severe chronic plaque psoriasis: review of clinical data. Part II
    • Papp K.A., Camisa C., Stone S.P., et al. Safety of efalizumab in patients with moderate to severe chronic plaque psoriasis: review of clinical data. Part II. J Cutan Med Surg 9 (2006) 213-323
    • (2006) J Cutan Med Surg , vol.9 , pp. 213-323
    • Papp, K.A.1    Camisa, C.2    Stone, S.P.3
  • 26
    • 49849083822 scopus 로고    scopus 로고
    • Raptiva (efalizumab) package insert. In: Genentech I, ed. Vol. 2007. South San Francisco; 2006.
    • Raptiva (efalizumab) package insert. In: Genentech I, ed. Vol. 2007. South San Francisco; 2006.
  • 27
    • 32544441226 scopus 로고    scopus 로고
    • Relapse, rebound, and psoriasis adverse events: an advisory group report
    • Carey W., Glazer S., Gottlieb A.B., et al. Relapse, rebound, and psoriasis adverse events: an advisory group report. J Am Acad Dermatol 54 4 Suppl 1 (2006) S171-S181
    • (2006) J Am Acad Dermatol , vol.54 , Issue.4 SUPPL. 1
    • Carey, W.1    Glazer, S.2    Gottlieb, A.B.3
  • 28
    • 17144388751 scopus 로고    scopus 로고
    • Extended efalizumab therapy improves chronic plaque psoriasis: results from a randomized phase III trial
    • Leonardi C.L., Papp K.A., Gordon K.B., et al. Extended efalizumab therapy improves chronic plaque psoriasis: results from a randomized phase III trial. J Am Acad Dermatol 52 (2005) 425-433
    • (2005) J Am Acad Dermatol , vol.52 , pp. 425-433
    • Leonardi, C.L.1    Papp, K.A.2    Gordon, K.B.3
  • 29
    • 32544448638 scopus 로고    scopus 로고
    • Practical guidelines for the long-term treatment of psoriasis with efalizumab
    • Leonardi C.L., Papp K.A., and Bos J.D. Practical guidelines for the long-term treatment of psoriasis with efalizumab. J Am Acad Dermatol 54 (2006) S153
    • (2006) J Am Acad Dermatol , vol.54
    • Leonardi, C.L.1    Papp, K.A.2    Bos, J.D.3
  • 30
    • 36148994531 scopus 로고    scopus 로고
    • Eruptive papules during efalizumab (anti-CD11a) therapy of psoriasis vulgaris: a case series
    • Lowes M.A., Chamian F., Abello M.V., et al. Eruptive papules during efalizumab (anti-CD11a) therapy of psoriasis vulgaris: a case series. BMC Dermatol 7 (2007) 2
    • (2007) BMC Dermatol , vol.7 , pp. 2
    • Lowes, M.A.1    Chamian, F.2    Abello, M.V.3
  • 31
    • 33747368253 scopus 로고    scopus 로고
    • Strategies for optimizing treatment with efalizumab in moderate to severe psoriasis
    • Papp K.A., Ho V., Langley R., et al. Strategies for optimizing treatment with efalizumab in moderate to severe psoriasis. J Cutan Med Surg 9 Suppl 1 (2005) 26-32
    • (2005) J Cutan Med Surg , vol.9 , Issue.SUPPL. 1 , pp. 26-32
    • Papp, K.A.1    Ho, V.2    Langley, R.3
  • 32
    • 49849092124 scopus 로고    scopus 로고
    • Product Monograph Part III: Raptiva. 2005.
    • Product Monograph Part III: Raptiva. 2005.
  • 33
    • 0027490541 scopus 로고
    • Localization of tumour necrosis factor-alpha (TNF-alpha) and its receptors in normal and psoriatic skin: epidermal cells express the 55-kD but not the 75-kD TNF receptor
    • Kristensen M., Chu C.Q., Eedy D.J., Feldmann M., Brennan F.M., and Breathnach S.M. Localization of tumour necrosis factor-alpha (TNF-alpha) and its receptors in normal and psoriatic skin: epidermal cells express the 55-kD but not the 75-kD TNF receptor. Clin Exp Immunol 94 (1993) 354-362
    • (1993) Clin Exp Immunol , vol.94 , pp. 354-362
    • Kristensen, M.1    Chu, C.Q.2    Eedy, D.J.3    Feldmann, M.4    Brennan, F.M.5    Breathnach, S.M.6
  • 34
    • 0142072978 scopus 로고    scopus 로고
    • TNFalpha as therapeutic target: new drugs, more applications
    • Reimold A.M. TNFalpha as therapeutic target: new drugs, more applications. Curr Drug Targets Inflamm Allergy 1 (2002) 377-392
    • (2002) Curr Drug Targets Inflamm Allergy , vol.1 , pp. 377-392
    • Reimold, A.M.1
  • 35
    • 15944428248 scopus 로고    scopus 로고
    • TNF alpha inhibitors in the treatment of psoriasis and psoriatic arthritis
    • Tobin A.M., and Kirby B. TNF alpha inhibitors in the treatment of psoriasis and psoriatic arthritis. BioDrugs 19 (2005) 47-57
    • (2005) BioDrugs , vol.19 , pp. 47-57
    • Tobin, A.M.1    Kirby, B.2
  • 36
    • 21644481166 scopus 로고    scopus 로고
    • A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction
    • Papp K.A., Tyring S., Lahfa M., et al. A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction. Br J Dermatol 152 (2005) 1304-1312
    • (2005) Br J Dermatol , vol.152 , pp. 1304-1312
    • Papp, K.A.1    Tyring, S.2    Lahfa, M.3
  • 37
    • 0344926414 scopus 로고    scopus 로고
    • Etanercept as monotherapy in patients with psoriasis
    • Leonardi C.L., Powers J.L., Matheson R.T., et al. Etanercept as monotherapy in patients with psoriasis. N Engl J Med 349 (2003) 2014-2022
    • (2003) N Engl J Med , vol.349 , pp. 2014-2022
    • Leonardi, C.L.1    Powers, J.L.2    Matheson, R.T.3
  • 38
    • 49849083149 scopus 로고    scopus 로고
    • European Medicines Agency. Enbrel [etanercept] summary of product characteristics.
    • European Medicines Agency. Enbrel [etanercept] summary of product characteristics.
  • 39
    • 49849087011 scopus 로고    scopus 로고
    • http://www.emea.eu.int/humandocs/Humans/EPAR/enbrel/enbrel.htm. Accessed 2005.
    • http://www.emea.eu.int/humandocs/Humans/EPAR/enbrel/enbrel.htm. Accessed 2005.
  • 40
    • 34250761386 scopus 로고    scopus 로고
    • Long-term safety and efficacy of 50 mg of etanercept twice weekly in patients with psoriasis
    • Tyring S., Gordon K.B., Poulin Y., et al. Long-term safety and efficacy of 50 mg of etanercept twice weekly in patients with psoriasis. Arch Dermatol 143 (2007) 719-726
    • (2007) Arch Dermatol , vol.143 , pp. 719-726
    • Tyring, S.1    Gordon, K.B.2    Poulin, Y.3
  • 42
    • 4644327125 scopus 로고    scopus 로고
    • Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomized, double-blind, placebo-controlled trial
    • Gottlieb A.B., Evans R., Li S., et al. Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomized, double-blind, placebo-controlled trial. J Am Acad Dermatol 51 (2004) 534-542
    • (2004) J Am Acad Dermatol , vol.51 , pp. 534-542
    • Gottlieb, A.B.1    Evans, R.2    Li, S.3
  • 43
    • 0043135095 scopus 로고    scopus 로고
    • Infliximab for psoriasis
    • Gottlieb A.B. Infliximab for psoriasis. J Am Acad Dermatol 49 2 Suppl (2003) S112-S117
    • (2003) J Am Acad Dermatol , vol.49 , Issue.2 SUPPL
    • Gottlieb, A.B.1
  • 44
    • 26644433889 scopus 로고    scopus 로고
    • Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial
    • Reich K., Nestle F.O., Papp K., et al. Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial. Lancet 366 (2005) 1367-1374
    • (2005) Lancet , vol.366 , pp. 1367-1374
    • Reich, K.1    Nestle, F.O.2    Papp, K.3
  • 45
    • 33646379583 scopus 로고    scopus 로고
    • The safety of infliximab, combined with background treatments, among patients with rheumatoid arthritis and various comorbidities: a large, randomized, placebo-controlled trial
    • Westhovens R., Yocum D., Han J., et al. The safety of infliximab, combined with background treatments, among patients with rheumatoid arthritis and various comorbidities: a large, randomized, placebo-controlled trial. Arthritis Rheum 54 (2006) 1075-1086
    • (2006) Arthritis Rheum , vol.54 , pp. 1075-1086
    • Westhovens, R.1    Yocum, D.2    Han, J.3
  • 46
    • 33845188387 scopus 로고    scopus 로고
    • Fistulating anal Crohn's disease: results of combined surgical and infliximab treatment
    • Hyder S.A., Travis S.P., Jewell D.P., Mc C.M.N.J., and George B.D. Fistulating anal Crohn's disease: results of combined surgical and infliximab treatment. Dis Colon Rectum 49 (2006) 1837-1841
    • (2006) Dis Colon Rectum , vol.49 , pp. 1837-1841
    • Hyder, S.A.1    Travis, S.P.2    Jewell, D.P.3    Mc, C.M.N.J.4    George, B.D.5
  • 47
    • 49849105371 scopus 로고    scopus 로고
    • Remicade (infliximab) package insert. Vol. 2007: Centocor; 2006.
    • Remicade (infliximab) package insert. Vol. 2007: Centocor; 2006.
  • 48
    • 49849087907 scopus 로고    scopus 로고
    • Hepatitis B reactivation associated with the anti-TNF products, Enbrel (etanercept), Humira (adalimumab) and Remicade (infliximab). In: Authrotiy NZMa MDS, ed: The Ministry of Health, New Zealand; 2006.
    • Hepatitis B reactivation associated with the anti-TNF products, Enbrel (etanercept), Humira (adalimumab) and Remicade (infliximab). In: Authrotiy NZMa MDS, ed: The Ministry of Health, New Zealand; 2006.
  • 49
    • 22544436130 scopus 로고    scopus 로고
    • Reactivation of latent granulomatous infections by infliximab
    • Wallis R.S., Broder M., Wong J., Lee A., and Hoq L. Reactivation of latent granulomatous infections by infliximab. Clin Infect Dis 41 Suppl 3 (2005) S194-S198
    • (2005) Clin Infect Dis , vol.41 , Issue.SUPPL. 3
    • Wallis, R.S.1    Broder, M.2    Wong, J.3    Lee, A.4    Hoq, L.5


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.